Foot Drop is a mobility disorder prevalent in patients that is a common result of neurological injuries or diseases such as stroke cerebral palsy, MS or brain tumors. Foot drop is characterized by the inability to lift the toes toward the shin. It inhibits the rhythmic swing phase of the gait, increasing the probability of falls and manifests in abnormal gait patters that inhibit mobility and create imbalances and stress. Currently, there is not a rehabilitative solution that is cost effective and practical for every day independent use. Dr. Tyler Susko has developed a shoe that provides a low-friction out-sole during the swing phase of the gait, and a high-friction out-sole during the stance phase of the gait. The design can be used on any style shoe. Preliminary pilot studies with impaired adults have shown immediate gait improvement.
AIFEN is developing a two stent, fenestrated aorto-iliac endograft system for repairs in atherosclerotic occlusive diseases. AIFEN is founded by Prof. Mohamed Zayed, the co-founder and CMO of Caeli Vascular. Dr. Zayed is a rising star in fostering innovation at Washington University in St. Louis, with 8 new medtech inventions over the past 3 years. His disclosures have lead to four patent filings and one license to his startup, Caeli.
AnelleO is a medical device company that is developing a 3D printed intravaginal ring that can be used as a platform for treating a wide range of women's health conditions. Their first product, AnelleO PRO involves the only single administration of progesterone for infertility. Their technology enables controlled drug-release kinetics with up to 100% drug release, as well as rapid manufacturing and custom sizing. The manufacturing method allows for formulation of biologics and drug combinations not possible with traditional technologies. AnelleO was founded by Rahima Benhabbour, professor at the Eshelman School of Pharmacy/UNC_NCSU Joint Biomedical Engineering Department, and Post Doctoral Fellow Rima Janusziewicz.
LEGIT uses a new optical concept (a lensguide) developed at Columbia University to improve optical endoscopy. Their goal is the development of a whole microscopy probe (size ~ 0.1-1 mm) that can be inserted in the body, with minimal damage, for high resolution imaging (<1 µm resolution). The LEGIT endoscopic probe can be used for cancer diagnostics (e.g. skin and liver cancer) and in vivo biopsy imaging. The LEGIT lensguide is a higher quality and less expensive replacement for the GRIN lenses with significantly higher flexibility in design and manufacturing.
Cellulograft is developing an implantable device for cell replacement therapy that protects cells from immune attack. Cellulograft is founded by Prof. Mohamed Zayed, the co-founder and CMO of Caeli Vascular. Dr. Zayed is a rising star in fostering innovation at Washington University in St. Louis, with 8 new medtech inventions over the past 3 years. His disclosures have lead to four patent filings and one license to his startup, Caeli.
Patients who undergo life-saving cardiac procedures (such as aortic valve replacement) are often exposed to a related harm: stroke, infarction, and brain injury. These strokes are due to the release of emboli, or particulate material such as a plaque, that travel in the blood from the heart to the brain during surgery. In response to a growing body of evidence of this problem, Lifeguard is a neuro-protective device that provides coverage to all three aortic arch takeoffs. Lifeguard is led by Yale Professor of Medicine Dr. Alexandra Lansky and Yale Associate Professor of Biomedical Engineering Dr. Tarek Fahmy.
The Blue Vertical-Cavity Surface-Emitting Laser (BlueVCSEL) is a breakthrough for projection, display technology, & lighting. Overcoming previous obstacles to commercialization, the team has utilized patented techniques to create the world's first stacking-fault-free semi-polar GaN-on-sapphire materials to make Blue VCSELs a commercial reality.
Phasis Biotech is a privately held biotechnology company, founded to develop the work of Cliff Brangwynne, a key architect of a new paradigm of intracellular organization through liquid-liquid phase separation (LLPS), which has deep implications for aggregation diseases. Phasis employs a novel set of technologies that use light to control phase separation and protein aggregation. These technologies are adaptable and can be applied to a wide range of systems. The initial focus is on developing these technologies into a platform for screening small molecules for their ability to disrupt aggregated protein phases associated with neurodegenerative diseases. The LLPS process plays a central role in devastating and currently untreatable diseases including Alzheimer’s and ALS.
The top 5 drugs sold are delivered by injection, 3 are biologics. Due to discoveries in fields like immuno-oncology, more of these high revenue drugs are biologics. Biologic drugs present a big promise, but they are met with a big problem: They are usually macromolecules, a fact that makes their formulations highly viscous and current injection devices require long injection times and larger gauge needles. The net result for patients is pain and discomfort and therefore reduced acceptance and compliance for treatments. AquaDrive (pka Inviscable) is developing a high performance actuator that could drive formulations 7x more viscous than any other technology currently available on the market, reducing the number of injections by half while minimizing device failure due to the robustness of the actuator at the core of the device.
Skin-penetrating catheters and lines, essential to medical management, carry downside risk of superinfection by migration of skin flora. The company is currently working on applying this technology to left ventricular assist devices (LVADs). Of the 2,700 LVADs implanted in 2015, there were 702 infections. There have been efforts to advance the standard of care and use bonded antibacterials, but these interventions have failed to date. The ultraviolet sterilizer transmits a narrow‐band ultraviolet light to a weave of optical fibers surrounding the driveline. Leakage of ultraviolet light will kill microorganisms attempting to migrate down the driveline, thus preventing infection and minimizing cost and toxicity associated with conventional approaches, including long‐term antibiotics and prosthetic device replacement.
LuminOva is developing a diagnostic to substantially improve the success rate of in-vitro fertilization (IVF). Infertility affects 15% of couples, yet IVF remains miserable and expensive. LuminOva has developed a diagnostic to reduce one of the biggest bottlenecks in IVF today - failure at transfer - by non-invasively and quantitatively measuring mitochondrial NADH and FAD levels to determine candidate embryo health pre-IVF.
Creating flexible batteries is essential to keep up with the development of flexible electronics. However, current technologies have failed to maintain high energy density in the flexible battery design. FlexFuture has created innovative and ﬂexible rechargeable batteries (FLEX. F series) which reduce design limitations in wearable devices and enable new breakthrough technologies of ﬂexible electronics. With unique structural designs, FLEX. F series have adaptable ﬂexibility and high energy density to enable stable deformability and longer-operation time in ﬂexible electronics, while maintaining cost-eﬀectiveness.
The vast majority, 95%, of drugs developed by companies to treat pancreatic cancer do not end up being approved. Vesselon's strategy for developing cancer therapies is not by finding new drugs, but by increasing the efficacy of existing approved drugs for cancer, starting with pancreatic cancer.
Neoadjuvant chemotherapy (NAC), given for 6 months prior to surgery, is widely applied as standard treatment for patients with newly diagnosed operable invasive breast cancer. The goal of NAC is a pathologic complete response (pCR) at surgery, as this response strongly correlates with survival. However, pCR is achieved in only 15-40% of women. Using a Dynamic Optical Tomographic Breast Imaging System (DOTBIS), physicians will be able to determine who will not respond to NACT soon after treatment initiation.
Tendo Technologies, founded in 2017, is a spin-off from the Marcus Hultmark research lab at Princeton developing a novel flow sensing/measurement technology. This unique technology achieves extreme sensitivity (for both gases and liquids) through the nanoscale conductive ribbons that will deflect when placed in flow. The nanoribbons are manufactured with standard semiconductor-based techniques, resulting in high scalability and low unit cost for the sensing chip. As a highly versatile technology (flow measurement is ubiquitous), Tendo envisions that their tech can be applied in many industries for various applications, when equipped with appropriate "wrappers" around it. For example, the Tendo chip plus communication package would be appropriate for IoT applications such as real time air measurement in HVAC ducts; alternatively, more sophisticated housing with control would bring benefits for flow metering and control during industry manufacturing processes.
An implantable, bone-anchored sympathetic nerve stimulator that can be used for treatment of chronic pain, hypertension, asthma, hyperactive bladder, and many other conditions.
Magnets form the core of a wide variety of power electronic devices including motors, inductors and transformers. New magnetic materials are needed to meet the high performance requirements for grid modernization (solid state transformers, PV inductors, sensors); for EVs and aviation (inductors, sensors, motors); and for industrial motor controls (inductors, sensors).
Hypnos is developing an in-ear, wearable EEG and ECG that is non-obstructive, discreet, and attractive to any user who wears earphones and would like to concurrently have real-time brain activity monitoring and feedback of measured variables to improve their cognitive performance and overall well-being. Audience choice winner for the Rothberg Catalyzer Prize at Yale.
Venohood is a custom cuff attachment to the venous end of an arteriovenous graft that reduces graft failure by lowering rate of thrombosis at the venous anastomosis. Venohood is founded by Prof. Mohamed Zayed, the co-founder and CMO of Caeli Vascular. Dr. Zayed is a rising star in fostering innovation at Washington University in St. Louis, with 8 new medtech inventions over the past 3 years. His disclosures have lead to four patent filings and one license to his startup, Caeli.
The current standard for distinguishing between benign and cancerous skin legions require an invasive skin biopsy followed by a waiting period for lab results for diagnosis. OptoVibronix is eliminating the need for invasive skin biopses to diagnose a skin legion as cancerous or benign. The technology scans the skin legion and results in a diagnosis in just 15 minutes. By avoiding skin biospy, it improves the patient experience and efficiency of diagnosis and reduces healthcare costs.
Genital herpes affects more than 500 million globally and it is incurable. In the US alone, 1 million people are diagnosed every year with herpes. Herpes causes painful viral outbreaks, significant psychological stress, and social stigma. Even though women are more prone to genital herpes, the available prevention option, condoms, is controlled by the male partner. The solution is a new female-controlled product called HerShield, a vaginally applied, soft and flexible pharmaceutical film that has proven safety in two phase I clinical trials, and provides sufficient quantities of drug for protection from herpes. HerShield is designed to be discrete, exceptionally portable, low cost, biodegradable, and easily self-administered without the need for an applicator.
This 3D printing technology (“Hybprinter”) can be used to form hybrid multi-material constructs incorporating a wide spectrum of materials (rigid and soft) and bioagents (such as cells and growth factors) with controlled spatial distribution in any XYZ coordinate across the hybrid structure. There are several technologies available to perform 3D bioprinting However, the main disadvantage is that only one type of material can be printed by many of these methods. However, due to its layer-by-layer manufacturing nature, Hybprinter enables the combination of cell-laden soft and hard biomaterials with a controlled spatial distribution for regenerative medicine applications.
Cardiac arrhythmias, including atrial fibrillation, put millions of Americans at risk of heart failure or stroke. OptiCardia has a heart visualization system giving the surgeon the ability to assess the effectiveness of Radiofrequency ablation in real time. The technology can result in more effective RF ablation and improve patient outcomes after the procedure.
Soft robotics shows promise for creating robots which are better able to navigate narrow and variable environments. The vine robot is able to extend its length many thousands of percent its body length with an internal pressurized vessel, which can be manipulated to change the direction of the robot tip. In testing, the vine robot is able to navigate through small passages and can even autonomously navigate towards light source with the addition of a camera.
In endoscopic surgery, the surgeon often has to remove the endoscope and clean the lens in order to fully visualize the surgical procedure. This wastes time and puts the patient at risk. The rotoscope is a self-cleaning endoscope which minimizes surgical time and risk to the patient.
Ear infections are the number on cause of doctors visits worldwide, affecting 700 million people each year. Chronic ear infections are often treated with the insertion of a tympanostomy tube into the ear drum. While these help to drain fluid, they often come with complications which can result in follow up surgeries and hearing loss. The PionEar tympanostomy tube technology addresses the most common complications by changing the geometry and materials of the tube to enhance fluid transport and reduce the chances of biofilm formation.
Arrhythmia symptoms range from shortness of breath and fatigue to sudden cardiac arrest or stroke. The disease also greatly decreases the quality of life by limiting physical activity and inducing a significant psychological burden. Catheter ablation is a minimally-invasive procedure that is one of the most effective treatments for arrhythmia. Unfortunately, nearly half of patients who undergo a first multi-hour ablation therapy will find that the procedure did not successfully treat their arrhythmia, will often time lead to new arrhythmias, and will most likely need to be repeated at least once. Visiblate is a software-based imaging technology that monitors and maps lesion formation in real time during catheter ablation surgery, reducing the likelihood of subsequent ablation procedures and reducing costs.
Wounds outside and inside the body are common and can be devastating. Wound adhesives have not been able to compete with suturing due to lack of strength and flexibility. LiMAX has developed a gel adhesive using biomimicry which is able to outperform existing medical adhesives in strength and flexibility. LiMAX is focusing on the application to skin first, but the applications of the technology span many tissues.
In the future, the power grid will be a large-scale network of distributed energy resources (DERs), each introducing random and rapid fluctuations in power supply, demand, voltage and frequency. These DERs provide tremendous opportunity for sustainability, efficiency, and power reliability. However, a major issue is how intelligent devices and independent producers can achieve maximum and reliable efficiency for the power network. Singularity's hardware-agnostic algorithmic platform can provide the intelligent control for the smart grid of the future.
Neuro-ICUs are faced with frequent shortcomings in maintaining brain care. Access requires one large or multiple smaller access points and devices require multiple external interface devices & monitors that frequently face challenges in the synchronization, analysis, and interpretation of data. The NeuroProbe System is a portable multimodal implant (EEG, temperature, oxygen, pressure, blood flow) that offers equal or better sensitivity via a single point of access along with synchronized sensor data via a single output connection. NeuroProbe has completed FDA pre-submission and developed prototype NeuroProbe and NeuroMonitor devices, with a system prototype demonstration ongoing in Summer 2019.
Stanford researchers have developed an architecture and control scheme for the coordination of distributed energy resources (DER), such as solar and storage, to minimize operation cost, enhance network reliability, and provide DER aggregation. The availability of electric load and generation data in electric grids varies both spatially and temporally due to: the random nature of loads and renewable generation; distributed locations of the loads and DER; and communication delays. Stanford researchers have found that control schemes that utilize local information (within the firmware of the storage unit, or in a home automation appliance) and delayed information to a global controller (e.g., collected from smart meter readings) perform near the ideal, but unimplementable, theoretical limit of performance.
Triple Endoscopy, Inc (TEI) is developing a multi-specialty single-use flexible endoscope system that enables widespread adoption of unsedated pediatric and adult endoscopy procedures and reduces their complexity, cost, and patient/provider apprehension.
Platform technology for sample optimization and pain control in minimally invasive devices for regenerative medicine, blood cancer, bone and soft tissue biopsy. Clinically relevant stem cell doses without culture or genetic manipulation, harvested and isolated at the bedside. Working in stealth mode for 2018.
Coated sutures are designed for improved mechanical resilience to prevent failure of surgical repair. Unlike conventional sutures, which concentrate stress at the point of attachment, these sutures use an adhesive coating and soft adhesive zone to distribute stress along the length of the suture and reinstate load transfer across the tendon‐to‐bone repair.
Knee cartilage injuries in young active people have unique challenges that do not face older patients. The treatments need to be able to withstand intense activity and last for years. There is currently no gold standard treatment, with all solutions having significant drawbacks in price, recovery time, and/or longevity of treatment. Nanochon has developed a 3D printed synthetic cartilage replacement which is inserted with minimally invasive surgery and encourages new tissue growth, extending the lifetime of the treatment.
A research team at the UMN has developed a system that predicts and optimizes the charge needed for commercial electric vehicles. The system is currently being applied to “last mile” delivery vehicles. The technology is a cloud-based software service that uses prior vehicle performance and external information like traffic and weather to train machine learning algorithms that, in turn, predict remaining vehicle range and battery state of charge. The result is a connected energy management system (C-EMS) that reduces range anxiety for fleet operators and enables greater penetration of electric vehicles into commercial fleets. The team, in conjunction with the UMN Venture Center, is seeking a business executive to form and launch a business with the research team and then lead and operate the business. C-VEM is already serving as the backbone to several companies providing solutions in this space.
Molecular Decisions provides boutique CRO services to pharmaceutical companies, helping them do faster and more confident drug development and clinical trials. The company analyzes clinical or analytical samples using nano-immunoassays that precisely measure specific protein isoform drug targets, enabling sound, immediate decisions related to drug efficacy.
CardinalSim utilizes information from CT scans to create a patient-specific virtual reconstruction of the surgical site for simulation.
Key nutrient deficiencies are more common than one may think and can lead to major health problems. However, determining vitamin levels can be costly, time-consuming, and confusing. VitaScan enables fast, accurate, and low-cost testing of an individual's vitamins and micronutrients. With VitaScan's portable system, the consumer can avoid hospital blood work and get the scan done at a physician's office, clinic, or even at home.
Revolution Reservoir is a self-powered, rotating catheter system to prevent shunt failure in patients with hydrocephalus. Revolution Reservoir is developed by Dr. Eric Leuthardt, one of the most prolific inventors at Washington University in St. Louis and the world with 628 Issued US patents and thousands of pending applications. He is the co-founder of 4 startup companies and is the director of the Center for Innovation in Neuroscience and Technology (CINT), which is sponsored by Stryker Corporation.
PETcoil enables healthcare providers to offer PET/MRI scans with better imaging quality for a fraction of the cost compared to existing solutions. Commercial integrated PET/MRI scanners cost ~$6M + ~$2M for required room renovations, an unaffordable cost for many institutions. PETcoil's patented portable PET insert can be placed into any existing MRI scanner, enabling it to perform simultaneous PET/MRI at 1/8th of the cost compared to integrated systems. A proof-of-concept radiofrequency (RF)-penetrable PET insert has been developed and successfully tested, supported by grants from the NIH, Stanford Bio-X & Biodesign programs, and the Coulter Foundation.
Myasthenia Gravis (MG) causes weakness and rapid fatigue of muscles under voluntary control and is caused by an antibody-mediated autoimmune response. Current treatment options include acetylcholinesterase inhibitors (with modest efficacy at improving neurotransmission). The prevalence in the U.S. is estimated at 20 cases per 100,000 people. The vaccine utilizes cytoplasmic domains of human AChR subunits and incomplete Freund’s adjuvant.
The use of radioisotope labels is ubiquitous in biochemistry, cell biology, drug discovery and numerous other fields, yet the approaches for detecting radioisotopes are more than four decades old. However, there is an unmet need for radioisotope detection materials that are more compatible with biological samples and that provide better temporal and spatial resolution. Scintillation Nanotechnologies develops and manufactures composite nanomaterials for detection of radioisotopes in biochemical and drug discovery applications. The proprietary composite nanomaterials provide a key enabling tool for established and new biochemical investigations that will directly impact human health. Scintillation Nanotechnologies has four products ready for immediate release to the market.
This device allows for damage free handling of sensitive devices and surfaces, and for applications that involve quick attach and release of surfaces. The total market opportunity for this company is approximately 36 billion. Conventional techniques to grab surfaces use a vacuum/suction strategy but these suffer an intrinsic limit of adhesion strength—1 atm (approximately 100 kPa) and are bulky. The switchable adhesion device is an electro-osmotic pump that uses individually-controlled oscillating water droplets to easily, carefully and quickly pick and place tiles in parallel.
Peritoneal carcinomatosis is a late stage manifestation of colon and ovarian cancer with a poor prognosis. Intraperitoneal (IP) chemotherapy is effective, but current methods lead to toxicity, which is not easily tolerated by patients. We propose a new approach, in which the chemotherapy drug is encapsulated in bioadhesive nanoparticles (BNPs) that can be delivered locally by established IP infusion methods. These BNPs are retained for many days in the IP space, and slowly release chemotherapy drugs, maximizing effectiveness, while minimizing toxicity.
Osteoporosis affects 50 million Americans and over 200M people worldwide. 50% of hip fracture sufferers lose ability to walk and 20% of suffers dye from it. Over 2M fractures and 300,000 hip fractures occur annually in the U.S. resulting in $20 billion and $12B in annual healthcare expenses, respectively. Currently, greater than 50% of the individuals with osteoporosis are not detected by bone density testing, the standard-of-care diagnostic test. This technology is a high-resolution MRI & CT analysis tool evaluating 3D bone structure and allowing for accurate assessment of (i) bone strength and health, (ii) osteoporosis development risk, and (iii) hip fracture risk. This imaging-based early diagnostic and prognostic for osteoporosis and hip fracture risk has data from over 1000 patients.
While surgical intervention via gastric bypass is effective in patients with obesity and type-II diabetes, the surgery is invasive, expensive and not reversible. Additionally, it is usually not prescribed for patients with BMI <40. Therefore, there is a need for a non-surgical alternative which is safer and less expensive but which mimics the effects of gastric bypass surgery. EndObypass achieves this with an implantable metal stent which runs through the stomach. The device mimics the anatomic and physiological changes caused by surgical procedures, resulting in dramatic weight loss and remission of diabetes. Animal studies with the implanted device have demonstrated proof of concept. The EndObypass technology provides a safe and affordable alternative to gastric bypass surgery.
SOVE is making a new approach for orthodontics. Traditional braces have never been comfortable or attractive, therefore there has been a large movement in the market towards invisible braces. However, many current 'invisible' alternatives suffer from a range of compromises that can make them under-perform. SOVE is developing the 2Insight, a two-stage orthodontic system that eliminate the problems associated with esthetic orthodontic appliances.
On-Demand Sustainable Hydrogen Energy. Hydrogen fuel cell technology can provide clean electricity - silently - with only water and heat as byproducts. However, 3 big hydrogen challenges remain: production, storage, and infrastructure. Hydropore is working to transform the current hydrogen production/storage paradigm through on-site hydrogen generation using only aluminum and water. Hydropore uses is proprietary research and technology to create nanoporous aluminum as a safe and efficient means of generating hydrogen for clean energy production.
Stenting is frequently used in Peripheral Artery Disease (PAD) to treat the symptoms of Atherosclerosis. However, this treatment has risks, including restenosis 60% of the time and late thrombosis that result in high re-intervention rates, non-healing ulcers, and higher risk for amputation. NuStent is developing an imageable, magnetic biodegradable intravascular scaffold as a new alternative to classical stents for PAD. In vivo porcine studies demonstrated safety and feasibility for deployment.